Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Comparative Randomized Study to Assess Safety and Efficacy and Select the Optimal Dosage Regimen of REMAXA®, Enteric-coated Tablets, in Comparison With REMAXOL®, Solution for Infusions, in Patients With Intrahepatic Cholestasis Caused by Chronic Diffuse Liver Diseases

NCT06183242 is registered in ClinicalTrials.gov with POLYSAN Scientific & Technological Pharmaceutical Company as lead sponsor.

NCT NCT06183242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06183242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Comparative Randomized Study to Assess Safety and Efficacy and Select the Optimal Dosage Regimen of REMAXA®, Enteric-coated Tablets, in Comparison With REMAXOL®, Solution for Infusions, in Patients With Intrahepatic Cholestasis Caused by Chronic Diffuse Liver Diseases
Lead sponsor
POLYSAN Scientific & Technological Pharmaceutical Company
Phase
Phase 2/3
Overall status
Completed
Start date
May 27, 2023
Completion date
October 10, 2024
Enrollment
328 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cholestasis, intrahepatic